手机购彩

The "Double Ai" program enters the national liver cancer diagnosis and treatment norms, providing superior results for patients with advanced hepatocellular carcinoma!
Primary liver cancer is the second leading cause of death worldwide, with high morbidity and mortality. China is a major liver cancer country, with nearly half of all liver cancer cases worldwide. With the rapid progress of scientific and technological innovation, liver cancer diagnosis and treatment have developed rapidly in the past two years, and many new high-level evidences in line with the principles of evidence-based medicine have appeared at home and abroad. More and more innovative drugs have entered the field of liver cancer treatment. In order to regulate and timely ...
2020-01-07
Heavy! Hengrui Medicine Class 1 New Drug Remazolam Tosylate for Injection Approved for Marketing
Recently, Hengrui Medicine received the Drug Registration Approval issued by the State Drug Administration, approving the company's Class 1 innovative drug Remazolam Toluenesulfonate (brand name: Rebinin) for listing. Remazolol tosylate for injection belongs to the benzodiazepine class. It is a new type of short-acting GABAa receptor agonist. It is metabolized by systemic plasma esterase, and its metabolites are inactive, and it has a fast acting effect ...
2020-01-02
Promoting Stability and Promoting Innovation——Hengrui Medicine's New Year Message in 2020
The age will change, and the day will be new. We are about to bid farewell to the extraordinary 2019 and move towards a new journey 2020 full of opportunities and challenges. At this moment of resignation, I would like to represent the company's management team to the employees and their families who have worked hard on all fronts and positions, and express their sincere gratitude to the leaders and friends from all walks of life who have cared, supported and helped the company for a long time. And sincere wishes!
2019-12-31
Hengrui Medicine: 2019 moves forward with change, dreams illuminate the distance
The order is easy, and Hua Zhang is new. Inadvertently, 2019 is about to leave us, and 2020 is striding towards us. This year was a landmark year for the great motherland. The 70th National Day celebrates the nation. This year, for Hengrui people, it was a year of advancing through the changes and meeting the difficulties. Hundreds of people struggling to flow, bravely set the tide, the hard-working Hengrui people stood more upright in the storm. ...
2019-12-31
Hengrui Medicine Class 1 New Drug Flurazole Pali Capsule Was Included in Priority Review
Recently, Hengrui Pharmaceutical's new class 1 drug, fluzopalyl capsules, as an innovative drug with obvious therapeutic advantages, has been included in the publicity list of priority products for review by the Drug Evaluation Center of the State Drug Administration. Fluroxaparil is a poly (ADP-ribose) polymerase (PARP) inhibitor, which can specifically kill BRCA-mutated tumor cells. It is used to treat the second-line and above ...
2019-12-09
New drugs approved by Hengrui Medicine for breast cancer and lung cancer
Recently, Hengrui Medicine received the "Clinical Trial Notification" for the company's pirlotinib tablets, SHR6390, and SHR-1316 injections approved by the State Drug Administration and approved the combination of pirlotinib tablets Randomized, double-blind, parallel-controlled, totuzumab plus docetaxel versus placebo combined with trastuzumab plus docetaxel for early or locally advanced HER2-positive breast cancer before surgery ...
2019-12-07
Heavy! Hengrui Pharmaceutical Celecoxib Capsule Approved for the First Time
Recently, Hengrui Medicine received the Drug Registration Approval issued by the State Drug Administration and approved the company's Celecoxib capsules for sale. Celecoxib is a non-steroidal anti-inflammatory drug that selectively inhibits COX-2. It is mainly used to relieve the symptoms and signs of osteoarthritis, adult rheumatoid arthritis and ankylosing spondylitis, and to treat acute pain in adults. The original drug was approved by the US FDA in 1998 ...
2019-12-06
Heavy! Hengrui Medicine Pirlotinib Maleate Tablets and Thiperifilastine Injected into National Medical Insurance Directory
Today (November 28), the National Medical Insurance Bureau, the Ministry of Human Resources and Social Security announced the full version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue" in 2019, and pyrrole maleate independently developed by Hengrui Medicine Tinib tablets and thiopefilgrastim injection were successfully negotiated and included in the national health insurance catalog
2019-11-28
上一页 1 2 3 4 5 ... 12 下一页 Total 95 recordsPrevious page 1 2 3 4 5 ... 12Next page